241 research outputs found
Catalytic Promiscuity of Transaminases : Preparation of Enantioenriched β-Fluoroamines by Formal Tandem Hydrodefluorination/Deamination
Transaminases are valuable enzymes for industrial biocatalysis and enable the preparation of optically pure amines. For these transformations they require either an amine donor (amination of ketones) or an amine acceptor (deamination of racemic amines). Herein transaminases are shown to react with aromatic β-fluoroamines, thus leading to simultaneous enantioselective dehalogenation and deamination to form the corresponding acetophenone derivatives in the absence of an amine acceptor. A series of racemic β-fluoroamines was resolved in a kinetic resolution by tandem hydrodefluorination/deamination, thus giving the corresponding amines with up to greater than 99 % ee. This protocol is the first example of exploiting the catalytic promiscuity of transaminases as a tool for novel transformations
Improving Care of Patients At-Risk for Osteoporosis: A Randomized Controlled Trial
BACKGROUND: Despite accurate diagnostic tests and effective therapies, the management of osteoporosis has been observed to be suboptimal in many settings. We tested the effectiveness of an intervention to improve care in patients at-risk of osteoporosis. DESIGN: Randomized controlled trial. PARTICIPANTS: Primary care physicians and their patients at-risk of osteoporosis, including women 65 years and over, men and women 45 and over with a prior fracture, and men and women 45 and over who recently used ≥90 days of oral glucocorticoids. INTERVENTION: A multifaceted program of education and reminders delivered to primary care physicians as well as mailings and automated telephone calls to patients. Outcome: Either undergoing a bone mineral density (BMD) testing or filling a prescription for a bone-active medication during the 10 months of follow-up. RESULTS: After the intervention, 144 (14%) patients in the intervention group and 97 (10%) patients in the control group received either a BMD test or filled a prescription for an osteoporosis medication. This represents a 4% absolute increase and a 45% relative increase (95% confidence interval 9–93%, p = 0.01) in osteoporosis management between the intervention and control groups. No differences between groups were observed in the incidence of fracture. CONCLUSION: An intervention targeting primary care physicians and their at-risk patients increased the frequency of BMD testing and/or filling prescriptions for osteoporosis medications. However, the absolute percentage of at-risk patients receiving osteoporosis management remained low
Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration
Background: Colorectal cancer (CRC) is the 3rd most common type of cancer worldwide. New anti-cancer agents
are needed for treating late stage colorectal cancer as most of the deaths occur due to cancer metastasis. A
recently developed compound, 3c has shown to have potent antitumor effect; however the mechanism underlying
the antitumor effect remains unknown.
Methods: 3c-induced inhibition of proliferation was measured in the absence and presence NAC using MTT in
HT-29 and SW620 cells and xCELLigence RTCA DP instrument. 3c-induced apoptotic studies were performed using
flow cytometry. 3c-induced redox alterations were measured by ROS production using fluorescence plate reader
and flow cytometry and mitochondrial membrane potential by flow cytometry; NADPH and GSH levels were
determined by colorimetric assays. Bcl2 family protein expression and cytochrome c release and PARP activation
was done by western blotting. Caspase activation was measured by ELISA. Cell migration assay was done using the
real time xCELLigence RTCA DP system in SW620 cells and wound healing assay in HT-29.
Results: Many anticancer therapeutics exert their effects by inducing reactive oxygen species (ROS). In this study,
we demonstrate that 3c-induced inhibition of cell proliferation is reversed by the antioxidant, N-acetylcysteine,
suggesting that 3c acts via increased production of ROS in HT-29 cells. This was confirmed by the direct
measurement of ROS in 3c-treated colorectal cancer cells. Additionally, treatment with 3c resulted in decreased
NADPH and glutathione levels in HT-29 cells. Further, investigation of the apoptotic pathway showed increased
release of cytochrome c resulting in the activation of caspase-9, which in turn activated caspase-3 and −6. 3c also
(i) increased p53 and Bax expression, (ii) decreased Bcl2 and BclxL expression and (iii) induced PARP cleavage in
human colorectal cancer cells. Confirming our observations, NAC significantly inhibited induction of apoptosis, ROS
production, cytochrome c release and PARP cleavage. The results further demonstrate that 3c inhibits cell migration
by modulating EMT markers and inhibiting TGFβ-induced phosphorylation of Smad2 and Samd3.
Conclusions: Our findings thus demonstrate that 3c disrupts redox balance in colorectal cancer cells and support
the notion that this agent may be effective for the treatment of colorectal cancer
- …